Business context and reporting period
Ekso Bionics Holdings, Inc. (the registrant named in the filing; not “Chronoscale Holdings Corp”) filed this Form 10-K for the fiscal year ended December 31, 2015. The company designs, develops and sells wearable exoskeletons, principally for rehabilitation, with additional engineering-services work and developing industrial and home-mobility markets. Unless noted otherwise, amounts below are in U.S. dollars.
Financial performance and condition
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $8.661 million | $5.327 million |
| Gross profit (margin) | $1.179 million (13.6%) | $1.559 million (29.3%) |
| Operating expenses | $22.740 million | $18.353 million |
| Operating loss | $(21.561) million | $(16.794) million |
| Net loss | $(19.590) million | $(33.769) million |
| Net cash used in operations | $(18.269) million | $(15.007) million |
| Cash at year-end | $19.552 million | $25.190 million |
- Revenue comprised $4.252 million from medical devices and $4.409 million from engineering services. The corresponding segment gross profits were $0.326 million and $0.853 million.
- Medical-device revenue rose 45%, partly from recognition of previously deferred device revenue; engineering-services revenue rose 83% as project activity increased.
- Medical-device service costs, including accelerated maintenance, field corrections and fleet upgrades, weighed on gross profit. Management said these costs were expected to increase in 2016.
- Year-end total assets were $32.198 million, total liabilities $23.390 million, and stockholders’ equity $8.808 million. Current assets were $25.201 million versus current liabilities of $8.619 million.
- Recorded liabilities included $9.195 million of warrant liability and $0.768 million of Equipois contingent consideration. Lease and leasehold-loan obligations were also reported; the filing’s contractual-obligations table totals $1.344 million, including operating leases and the Equipois supply commitment.
Changes versus the prior year and unusual items
- Revenue increased 63%, but gross profit fell 24% and operating loss widened 28%, reflecting faster growth in costs and operating expenses than in revenue.
- Net loss narrowed substantially versus 2014, largely because of non-cash warrant accounting: 2015 included a $2.505 million gain from a lower warrant liability, while 2014 included a $16.485 million warrant-liability loss. The improvement in net loss therefore did not reflect improved operating performance.
- The December 2015 registered direct financing issued Series A convertible preferred stock and warrants for $15.0 million gross proceeds; net financing cash proceeds were $13.906 million. The transaction included warrants for up to 14.851 million common shares, recorded as a liability, and produced $4.655 million of non-cash preferred deemed dividends. Preferred shares had a $1.01 conversion price and down-round protection.
- In December 2015, the company acquired substantially all Equipois assets for an initial 781,250 common shares, with estimated total consideration of $1.839 million including contingent consideration. The acquired technology and products included zeroG and X-Ar.
- Fourth-quarter 2015 revenue was $1.943 million, gross loss was $0.194 million, and net loss was $4.645 million; loss attributable to common shareholders was $9.300 million, including preferred deemed dividends.
Outlook, risks and contingencies
- Management estimated cash runway into the first quarter of 2017, based on average monthly net cash use of approximately $1.5 million and assumptions about revenue, spending and rental activity. It anticipated needing additional financing within two to four quarters; no financing arrangements were then in place. Failure to raise capital could require spending reductions or curtailed operations.
- Management’s 2016 priorities included pursuing FDA clearance for Ekso GT, initiating company-sponsored clinical work, developing next-generation home-mobility technology and advancing industrial products. The filing gives no quantified revenue or earnings guidance.
- The FDA had created a Class II powered-exoskeleton classification requiring 510(k) clearance and had issued the company an Untitled Letter. The company submitted a 510(k) in 2014, received an FDA request for further information, and responded on March 2, 2016, after year-end. The application remained pending; management expected a determination in 2016, but clearance was not assured. The company continued marketing under its existing registration, which the FDA could challenge.
- An FDA inspection in September 2015 resulted in a Form 483 with observations concerning informed consent, adverse-event reporting and records. The company described corrective actions; the inspection was not a final determination of non-compliance. Seven reportable device events had been identified since July 1, 2015, with no reported patient injuries; the company said it filed required reports and implemented design, manufacturing and maintenance changes.
- Key risks include ongoing losses and cash burn, dependence on additional financing, unproven market adoption and reimbursement, regulatory and clinical uncertainty, product reliability and potential liability, competition, supplier concentration, and possible shareholder dilution from preferred stock, warrants and equity awards.
- The company reported that a previously identified material weakness in internal control was remediated in the fourth quarter of 2015. Management and the auditor concluded internal control over financial reporting was effective at year-end; the financial-statement audit opinion was unqualified.
Most important facts for investors to verify
- Whether the FDA cleared the Ekso GT, on what indications, and whether further clinical evidence or restrictions were required.
- Actual cash burn and financing needs against management’s stated runway into Q1 2017; check subsequent financing and any resulting dilution.
- Whether device revenue growth can translate into better gross margins as service, maintenance and fleet-upgrade costs evolve.
- The potential dilution and accounting impact of the 14.851 million warrants, preferred-stock conversion and anti-dilution terms.
- Clinical outcomes, reimbursement progress, repeat sales and utilization at rehabilitation customers, alongside industrial and Equipois commercialization progress.